NICE has published guidance on pharmacological interventions for weight management, including NICE guideline CG189 (Obesity: identification, assessment and management) and a technology appraisal supporting the use of semaglutide (Wegovy) for adults with a BMI of 35 kg/m or above (or 3034.9 kg/m in certain circumstances) alongside a specialist weight management service
Founded with a mission to create a holistic and personalized alternative to traditional, one-size-fits-all weight-loss solutions, we meet each person where they are on their unique journey, empowering them to confidently take control of their well-being at every step of the way
Every cagrilintide protocol begins with a complete metabolic evaluation, complete metabolic panel, hormone testing, body composition analysis, and a detailed history of previous attempts, before the first injection
Most adults on GLP-1 medications need significantly more protein than they can comfortably eat from food alone